ERNESTO
CANO RUBIO
Investigador en el periodo 1989-2018
Enrique
Raviña Rubira
Publicaciones en las que colabora con Enrique Raviña Rubira (9)
2017
-
3-Oxopyridazin-5-yl-Chalcone Hybrids: Potent Antiplatelet Agents That Prevent Glycoprotein IIb/IIIa Activation
ChemistrySelect, Vol. 2, Núm. 17, pp. 4920-4933
2007
-
Design, synthesis, and structure-activity relationships of a novel series of 5-alkylidenepyridazin-3(2H)-ones with a non-cAMP-based antiplatelet activity
Journal of Medicinal Chemistry, Vol. 50, Núm. 26, pp. 6476-6484
2006
-
Pyridazines part 41: Synthesis, antiplatelet activity and SAR of 2,4,6-substituted 5-(3-oxo-3-phenylprop-1-en-1-yl)- or 5-(3-phenylprop-2-enoyl) pyridazin-3(2H)-ones
Bioorganic and Medicinal Chemistry Letters, Vol. 16, Núm. 4, pp. 1080-1083
2004
-
Pyridazines. Part 36: Synthesis and antiplatelet activity of 5-substituted-6-phenyl-3(2H)-pyridazinones
Bioorganic and Medicinal Chemistry Letters, Vol. 14, Núm. 2, pp. 321-324
2002
-
Pyridazines. Part 31: Synthesis and antiplatelet activity of 4,5-disubstituted-6-phenyl-3(2H)-pyridazinones
Chemical and Pharmaceutical Bulletin, Vol. 50, Núm. 12, pp. 1574-1577
1999
-
Pyridazines XVIII. 6-Aryl-3(2H)-pyridazinones inhibit calcium influx in stimulated platelets
Biological and Pharmaceutical Bulletin, Vol. 22, Núm. 12, pp. 1376-1379
1997
-
Pyridazines. XIII. Synthesis of 6-aryl-5-oxygenated substituted-3(2H)- pyridazinones and evaluation as platelet aggregation inhibitors
Chemical and Pharmaceutical Bulletin, Vol. 45, Núm. 7, pp. 1151-1155
1990
-
6-aryl-5-amino-3(2H)-pyridazinones as platelet aggregation inhibitors
Scientia Pharmaceutica
-
Synthesis of 6-aryl-5-substituted 3(2H)pyridazinones as inhibitors of platelet aggregation
Scientia Pharmaceutica